Significant infectious comorbidities including invasive fungal disease, B. Cepacia, non TB mycobacteria, or TB.
Receipt of JAK inhibitor therapy after lung transplant for any indication. Treatment with a JAK inhibitor before lung transplant is permitted.
Laboratory values at screening outside the protocol-defined ranges.
Active HBV or HCV infection that requires treatment, or at risk for HBV reactivation (ie, positive HBsAg).
Known HIV infection.
History of active malignancy within 3 years of screening.
Women who are pregnant or breastfeeding.
Treatment with an investigational agent, procedure, or device within 30 days of enrollment, or within 5 half-lives of the investigational product, whichever is longer.
